Marina Baretti is an Oncology physician affiliated with Bloomberg. OpenAlex indexes 187 publications with 1,866 citations (h-index 19); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1650 Orleans St # Street1
Baltimore, MD 212870013
Telephone
410-614-1058Provider last certified this registry record 11 Mar 2022.
Clinical trials
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20251 payment
- Incyte CorporationProgram year20235 payments
- AstraZeneca Pharmaceuticals LPProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
33.3%l-Thyroxine33.3%Levothyroxine Sodium100%Part D<11 patientsBlood & clotting
24.1%Factor Xa inhibitor24.1%Eliquis100%Part D<11 patientsMetabolism & gastrointestinal
22.2%Corticosteroid22.2%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial
Nature Communications
2026 - Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade
Journal for ImmunoTherapy of Cancer
2025 - Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging
Hepatology Communications
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Arturo Casadevall, MD
Bloomberg
Elizabeth Jaffee, MD
Bloomberg
Daniel Laheru, MD
Bloomberg
William Sharfman, MD
Bloomberg
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”